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1. Introduction 
Melanoma is an aggressive skin cancer that has an occurrence rate of about 1 in every 50 
Americans (Giblin & Thomas, 2007). It is the 6th most common cancer, with a lifetime risk of 
2.04% for men and 1.38% for women (Jemal et al., 2008; Jilaveanu et al., 2009). According to 
the American Cancer Society, in 2009 the number of new cases of melanoma rose to 68,720 
with 8,650 new deaths attributed to the disease (ACS, 2010). There are many known factors 
that contribute to the formation of melanoma. One major factor influencing the increase in 
melanoma cases is increased exposure to ultra-violet radiation (UVR). Other risk factors 
include skin type, hair/eye color, the presence of dysplastic nevi and/or increased nevi, and 
a family history of melanoma (Jilaveanu et al., 2009). Also, mutations in BRAF, CDKN2A, 
and CDK4 genes have all been attributed to melanoma development. BRAF mutations have 
been found in 70% of all melanomas and greater than 90% of these mutations carry a single 
missense (single nucleotide change) mutation (Meyle & Guldberg, 2009). CDKN2A is 
involved in melanoma pathogenesis and is a germline mutation found in younger patients 
(Liu et al., 2007). CDK4 is involved in cell-cycle arrest and has been identified in 10% of 
melanomas (Bennett, 2008). These mutations are mostly detected in non-chronic sun-
induced damage melanomas, while chronic sun-induced damage melanomas are more 
commonly observed.  
When melanoma arises, early diagnosis is crucial to survival. With early diagnosis, more 
than 80% of cases can be treated successfully through surgery (Zhu et al., 2009). This surgery 
includes excision of the tumor and surrounding tissue; lymph nodes near the tumor may 
also be removed if evidence of metastasis is present. Other treatments for melanoma include 
radiation and chemotherapy, used particularly in cases of highly aggressive and metastatic 
disease (ACS, 2010). Side-effects from these treatments include fatigue, malaise, and an 
increased susceptibility to non-melanoma cancers (Kamposioras et al., 2010). Also, these 
therapies are severely toxic to the patients, suggesting a need for improved, less toxic 
treatment options that specifically target melanoma tumors, like immunotherapy. The 
multiple ways that melanoma alters the immune system locally, at the site of the tumor, and 
systemically makes the disease difficult to treat but ideal for the study of 
immunomodulation (Berinstein, 2009). Immunomodulation, the alteration of the immune 
system or its function, is exploited in multiple forms by melanoma tumors from changes in 
the cellular and sub-cellular makeup of the tumor to changes in the tumor 
microenvironment that suppress localized and systemic attempts at disease reduction.  
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At the cellular level, melanoma tumors differentially express cytokines, chemokines, and 
soluble molecules responsible for immunosuppression and tumor proliferation which will 
be discussed further in this chapter, particularly those with potential for targeting or with 
therapeutic benefits (Lazar-Molnar et al., 2000). Melanoma cells are also less efficient in 
antigen (Ag) presentation to CD4+ T cells, reducing immune detection of melanoma tumors 
and the effectiveness of some immunotherapy strategies (Norton & Haque, 2009). Multiple 
defects along the HLA class II pathway are present in melanoma cells, the alteration of 
which could prove useful in novel tumor targeting and immunotherapeutic vaccination 
strategies. These defects and the potential to overcome them will be further explained in this 
chapter. Costimulatory molecules are also altered in melanoma cells, reducing positive 
cellular interaction with T cells and professional antigen presenting cells (APCs), while 
promoting immunosuppressive interactions through CD28, CTLA-4, and the B7 family of 
immune inhibitors (Pardee et al., 2009; Wolchok & Saenger, 2008). Study focused on 
enhancing these secondary stimulation signals would promote complete T cell stimulation 
and activation of anti-tumor CD8+ T cells, a current goal of most immunotherapy strategies.  
Melanoma cells are also capable of modulating the surrounding immune cells including: 
suppression of tumor infiltrating lymphocytes (TILs), enhancement of CD4+CD25+FoxP3+ T 
regulatory cells (Tregs), increased immature myeloid suppressor cells, increased pro-
tumorigenic m2 macrophages, and generation  of melanoma-associated fibroblasts (Oble et 
al., 2009; Camisaschi et al., 2010; Balsamo et al., 2009; Ilkovitch & Lopez, 2008). These topics 
will be further dissected throughout the chapter as they relate to both immune suppression 
and multimodal treatment strategies. The course of tumor progression not only adds more 
problems to immune regulation of the disease, but also more potential targets for therapeutic 
intervention. Melanoma angiogenesis and metastasis aggravate immune suppression in 
distinct and specific ways increasing the morbidity and mortality of the disease, while 
reducing the effectiveness of current treatment options (Schadendorf et al., 2009; Zbytek et al., 
2008; Mahabeleshwar & Byzova, 2007). Both of these topics will be further examined with 
specific emphasis on the relationship between Interleukin (IL)-8, vascular endothelial growth 
factor (VEGF), the matrix metalloproteinases (MMPs), and the distinct problems faced when 
tumors metastasize, particularly to lymph nodes, the lungs, liver, and brain (Sloan et al., 2009; 
Vahrmeijer et al., 2008; Huang et al., 2008; Yang et al., 2009).  
Melanoma also represents one of the most widely studied tumors in terms of 
immunotherapy design, clinical evaluation, and therapeutic application (Jandus et al., 2009). 
This chapter will discuss the successes and failures of melanoma immunotherapy strategies 
like IL-2 therapy, melanoma vaccines like canvaxin, and adoptive cell transfer in terms of 
immunomodulation and its effect on treatment (Atkins, 2006; Goldman & DeFrancesco, 
2009). This chapter will also discuss current strategies being developed and potential new 
directions in treatment that address the immunomodulatory nature of melanoma. These 
include combined chemoimmunotherapy, melanoma monoclonal antibodies, and 
multimodal therapy strategies (Kudo-Saito et al., 2005; Ascierto et al., 2010; Flaherty, 2006). 
The goal of this chapter is to summarize the multiple roadblocks in melanoma treatment 
associated with the immunomodulation instigated by melanoma tumors. By understanding 
these issues, novel targets for melanoma therapy can be developed and the shortcomings of 
current treatment modalities can be enhanced leading to improved patient care and patient 
outcomes. The fight against melanoma in many ways is a war of attrition: gradual gains can 
and must be made by making treatment more effective through improved knowledge of the 
immunomodulatory mechanisms that melanoma tumors employ. 
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2. The tumor microenvironment 
When discussing the ability of melanoma tumors to induce both local and systemic 
immunomodulation, it is important to first understand the tumor microenvironment itself, 
and how the alterations at this level affect both tumor progression and limit the 
effectiveness of some treatment strategies. Melanoma arises through a complex process of 
cellular mutation and a loss of keratinocyte control over melanocyte growth and 
differentiation (Hsu et al., 2002; Shirakata, 2010). This imbalance leads to the formation of 
early stage nevi, appearing localized near the basement membrane of the skin. As malignant 
melanoma progresses, it develops through interaction between dysfunctional melanocytes 
and the tumor microenvironment. The progression from nevocellular nevi to dysplastic nevi 
is accompanied with changes in both keratinocytes and local adhesion molecules allowing 
for increased melanocyte-melanocyte interaction and the formation of nevocyte nests at the 
dermal-epidermal junction (Danen et al., 1996; Hsu et al., 2002). Following this 
development, melanocytes fail to respond to keratinocyte or epidermal cell signaling, they 
no longer form dendrites, and start to modulate the immune environment through the 
release of cytokines and immune activation factors which will be described in this chapter 
(Ilkovitch & Lopez, 2008). Tumors next proceed through two distinct growth phases, radial 
and vertical growth, accompanied by increased inflammation, immune modulation, and 
healthy cell destruction. In this sense, the abuse of the immune system drives the 
progression of disease to a more aggressive phenotype, again through shed factors which 
will be further explained in this chapter. Finally, following vertical growth through the 
basement membrane of the dermis following periods of high angiogenesis, melanoma cells 
are now free to metastasize to local and distant sites resulting in poor disease prognosis (Ria 
et al., 2010). This section will also focus on the distinct ways melanoma cells respond to the 
tumor microenvironment during the course of melanoma progression, and how these 
alterations could be exploited in developing novel melanoma therapies.  
2.1 Shed molecules and immunosuppression 
At the cellular level, melanoma tumors differentially express cytokines, chemokines, and 
soluble molecules responsible for immunosuppression and tumor proliferation. Initially, 
these molecules can have regulatory roles in the tumor microenvironment through growth 
inhibition, but these functions are lost as tumors slowly progress to a state of localized 
immune suppression (Lu & Kerbel, 1993). Table 1 is a brief summary of some of the 
cytokines and growth factors associated with melanoma progression and 
immunosuppression. A more thorough examination of these factors is expertly presented in 
a review by Ilkovitch et al (Ilkovitch & Lopez, 2008). 
Some cytokines appear to have dual roles within the tumor microenvironment depending 
on the stage and advancement of disease. During initial tumor formation the inflammatory 
cytokine IL-6 shed by localized keratinocytes, epithelial, and immune cells inhibits tumor 
proliferation. IL-6-induced growth inhibitor during early stages of melanoma garnered 
some attention as an immunological target, but clinical application failed to show any 
benefit (Lu & Kerbel, 1993). During late stages of disease, IL-6’s control of over-growth is 
lost and autocrine usage of IL-6 produced by melanoma cells actively enhances tumor 
progression through the STAT3 pathway, which can be further enhanced through 
interactions with IL-17 (Wang et al., 2004; Hodge et al., 2005; Wang et al., 2009). Elevated 
STAT3 activity regulates tumor oncogenic factors, cell survival, and cell proliferation 
 
www.intechopen.com
 Treatment of Metastatic Melanoma 
 
118 
Molecule Role
IL-1(ǂ and ǃ) Melanoma derived IL-1ǂ and IL-1ǃ induce fibroblast and endothelial growth factors 
as well as surface adhesion molecules allowing for the growth and metastasis of 
melanoma cells, also can stimulate IL-6 production.
IL-6 Initial tumor suppression, then stimulates tumor growth through autocrine 
regulation by activating Stat3, IL-17 can also be induced in this system further 
stimulating Stat3.
IL-8 Highly involved in angiogenesis through chemoattraction of infiltrating 
lymphocytes and cell adhesion regulation.
IL-10 Anti-inflammatory, induces T cell and DC suppression, can be excreted by tumors 
and by tolerized or regulatory T cells.
IDO Inhibits T lymphocyte mediated antigen-specific immune responses through 
suppression of tryptophan, also promotes immune tolerance.
FasL Melanoma cells lack functional FasL, which prevent FasL interaction with Fas
receptor on lymphocytes, and modulate apoptosis induction. 
TGF-ǃ Multiple roles in immunosuppression, can be secreted by melanoma tumors acting 
in both autocrine and paracrine manner, converts immune cells to suppressive 
regulatory phenotype.
PGE2 Released from melanoma associated fibroblasts, inhibits NK T cell activity and adds 
to immunosuppression.
 
Table 1. Immunomodulatory Molecules Influencing Melanoma Growth 
molecules resulting in angiogenesis, tumor growth, and in some cases (i.e. brain) metastasis 
(Xie et al., 2006). Similarly to IL-6, TGF-ǃ also displays growth inhibitor paracrine function 
during early stages of disease, and autocrine tumor growth in later stages of progression 
(Ma et al., 2009; Pardali & Moustakas, 2007).  
Anti-inflammatory cytokines and immunomodulatory molecules are often exploited by 
melanoma cells, most notably IL-10. Melanoma cells, melanoma recruited myeloid 
suppressor cells, and Tregs actively secrete IL-10 to induce tolerized T cells and dendritic 
cells (DC) (Huang et al., 1999; Polak et al., 2007). The chemokine IL-8 also plays a major role 
in melanoma progression, particularly in angiogenesis. Autocrine produced IL-8 can 
stimulate melanoma growth and induce expression of cellular adhesion molecules allowing 
for tumor cell migration. The chemoattractant nature of IL-8 also allows for the recruitment 
of monocytes and macrophages to the tumor site which release growth factors modulating 
vascular permeability contributing to cell migration. The tumorigenic properties of IL-8 are 
well summarized by Waugh and Williams (Waugh & Wilson, 2008). Based on these 
characteristics, targeting IL-8 could reduce the angiogenic nature of melanoma cells 
allowing for improved clearance of tumors, an area that should be further studied for its 
therapeutic potential. Additionally, two shed molecules indoleamine-2,3-deoxyginase (IDO) 
and prostaglandin E2 (PGE2) also contribute to melanoma induced immunosuppression and 
represent interesting potential targets in immunotherapy design. IDO is produced primarily 
by suppressive lymphocytes and immature myeloid/dendritic cells. IDO also acts as a 
tryptophan sink in the tumor microenvironment, severely inhibiting T cell activation (Polak et 
al., 2007; Honig et al., 2004). Recent study suggests that PGE2 is produced by melanoma-
associated fibroblasts and immature myeloid cells and aids in the recruitment of a specific 
lineage of migratory DC with low cytokine expression profiles (Luft et al., 2002). PGE2 also 
inhibits NK T cell anti-tumor activity contributing to immunosuppression in the tumor 
microenvironment (Balsamo et al., 2009). Taken together, these molecules represent hurdles to 
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most immunotherapy strategies employed, which rely on the state of the immune system at 
the time of treatment to overcome the tumor burden. Steps should be taken to inhibit PGE2 
and IDO, as well as the suppressive cytokines mentioned prior to immunotherapy, allowing 
for a more robust immune response. These cytokines are not solely responsible for the 
deficiency in current treatment strategies; the cellular makeup of TILs and the melanoma-
associated neighboring cells may play major roles in immune subversion. 
2.2 Immune cells 
As seen in the description of shed molecules, there is dynamic crosstalk between tumors and 
surrounding tissues and infiltrating immune cells that result in both tumor challenge and in 
tumor progression. Often, autocrine and paracrine signaling pathways between melanoma 
cells and surrounding cells contribute to tumor progression and metastasis as reviewed by 
Lazar-Molnar et al (Lazar-Molnar et al., 2000). The shift from tumor suppression to tumor 
progression and metastasis results, in part, from the alteration in the type and characteristics 
of TILs. These changes include the enhancement of CD4+CD25+FoxP3+ Tregs, increased 
immature myeloid suppressor cells, increased pro-tumorigenic m2 macrophages, and the 
generation of melanoma-associated fibroblasts (Kalluri & Zeisberg, 2006; Mantovani et al., 
2002; Almand et al., 2001; Bronte et al., 2001). From a treatment perspective, understanding 
the alterations in immune cells localized to the tumor site provides both the reason for the 
failures of some immunotherapy and some novel ways to treat the disease. As stated 
previously, the progression from healthy melanocyte to melanoma occurs through both 
mutations within the tumor and through alterations of the cellular environment around the 
melanoma. In the skin, tissue homeostasis is critical in cellular regulation as well as immune 
control, and melanoma tumors disrupt this regulation through multiple processes.  
Melanoma cells release high levels of basic fibroblast growth factor (bFGF) which results in 
the generation and localization of melanoma-associated fibroblasts to the tumor 
microenvironment (Meier et al., 2000). These cells are unlike normal skin fibroblasts in that 
they proliferate rapidly and eventually outnumber most other cell types within the tumor 
microenvironment (Li et al., 2003; Lee et al., 2005). They also release molecules that support 
the growth and movement of melanoma tumors in the extracellular matrix (ECM) of 
surrounding tissue and affect the function of NK T cells, aiding in immune inhibition 
(Balsamo et al., 2009). Melanoma tumors also recruit immune suppressor cells such as 
immature dendritic cells, myeloid derived suppressor/immature myeloid cells, and M2 
macrophages (Kusmartsev & Gabrilovich, 2006; Bronte et al., 2001; Hanson et al., 2009). 
These cells work together releasing immunosuppressive molecules like TGF-ǃ, IL-1ǂ, IDO, 
IL-10, PGE2, and reactive oxygen species (ROS) (Kusmartsev & Gabrilovich, 2003; Almand 
et al., 2001; Valenti et al., 2006). Functionally, these cells are deficient in melanoma tumor 
antigen presentation, resulting in indirect tumor tolerance through interaction with CD8+ T 
cells (Almand et al., 2001). These factors work against the anti-tumor infiltrating 
lymphocytes creating a network of immune suppression surrounding the tumor, and 
through localized inflammation and dysregulation of cell adhesion molecules, they aid in 
tumor growth, movement, and angiogenesis (Brigati et al., 2002). Thus, targeting these cells 
in combination with melanoma tumors should improve the efficacy of immunotherapy 
strategies, such as targeting shared signaling pathways between tumors and surrounding 
tissue like STAT3 and BRAF/MAPK (Sumimoto et al., 2006; Inamdar et al., 2010).  
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Figure 1 illustrates the cells melanoma tumors induce for their benefit and the effect that they 
have on anti-tumor immunity. When discussing melanoma immunosuppression, one cannot 
leave out the role that T cells play in the tumor microenvironment, in particular the 
detrimental role of FoxP3+ Tregs, reviewed by Oble et al (Oble et al., 2009). Tregs are normally 
involved in regulating immune responses to avoid autoimmunity and in reigning in the 
cytolytic effects of effector CD8+ T cells. They represent the suppressive arm of CD4+ T cells, 
and are best identified by their high expression of CD25 and FoxP3 (Camisaschi et al., 2010; 
Vence et al., 2007). In melanoma, particularly in advanced disease states, Tregs are the primary 
infiltrating lymphocyte where they directly inhibit any cytotoxic antitumor activity through 
direct contact inhibition, and the release of high levels of IL-10 (Baumgartner et al., 2007). 
Study suggests that high serum concentrations of Tregs are associated with poor prognosis, 
poor treatment responses, and an increased risk of recurrence (Vence et al., 2007). 
 
 
Fig. 1. Microenvironment and immune cell dysfunction. A. Melanoma cells recruit 
melanoma-associated epithelial and immune cells. These include fibroblasts (FB), immature 
dendritic cells (iDC), myeloid derived suppressor cells (MDSC), M2 macrophages (M2 M). 
And CD4+CD25highFoxP3+ T cells (FoxP3+Treg) which release molecules like IL-10, IL-
1R, IDO, TGF-, VEGF, and ROS that can inhibit antitumor activity and promote tumor 
growth. B. Melanoma cells directly interfere with limiting endothelial and immune cells like 
keratinocytes (KCS), NK T cells (NK T), cytotoxic lymphocytes (CD8+), and CD+ effector 
cells (CD4+) through the expression of TGF-, shed and surface FasL, and IL-6. 
Tregs are also found in high numbers in sentinel lymph nodes and peripheral blood in cases 
of metastatic melanoma where they interfere with the expansion of CD8+ and CD4+ effector 
cells trough IL-2 suppression (Viguier et al., 2004). Study in mice revealed that Treg 
depletion resulted in the expansion of highly reactive CD8+ T cells resulting in tumor 
clearance, and in human studies, depleting lymphocytes prior to adoptive cell transfer 
(ACT) improved the effectiveness of treatment (Mahnke et al., 2007; Matsushita et al., 2008). 
These results could be associated with the deletion of the large pool of Tregs in the tumor 
microenvironment and represent an important immunotherapeutic option going forward. 
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The multiple ways of targeting these immunosuppressive cells in therapy design will be 
highlighted later in this chapter.  
3. Melanoma antigen processing and presentation 
In conjunction with these observed deficiencies in the tumor microenvironment leading to 
immune dysfunction, it is important to understand the direct interplay between melanoma 
tumors and the immune cells attempting to regulate and destroy tumors. Much focus has 
been paid to the suppressive nature of Tregs, yet melanoma cells have their own 
mechanisms of directly inhibiting CD8+ cytotoxic and CD4+ effector T cells (Viguier et al., 
2004; Lampen & van Hall, 2011; Norton & Haque, 2009). CD8+ and CD4+ T cells interact 
with melanoma tumors through contact with HLA class I and HLA class II molecules on 
their cell surface, respectively. Multiple defects exist in melanoma cells ranging from 
complete loss of class I and II expression to subversive Ag generation attributed to defects in 
endosomal/lysosomal machinery. These issues and how they represent novel mechanisms 
for disease treatment and immunotherapy design will be discussed in this section. 
3.1 Antigen processing and presentation 
The general consensus when describing immunological strategies against melanoma is in 
the induction of a cytotoxic immune response mainly generated by the activation of anti-
tumor CD8+ T cells. Though CD8+ T cells perform the bulk of the tumor destruction, by 
focusing solely on activating these cells and not CD4+ T cells, melanoma tumors are capable 
of devising strategies to avoid CD8+ T cell detection and activation. Clinical evidence 
supports this notion, as even in patients with advanced disease there are detectable CD8+ T 
cells specific for melanoma tumor Ag, yet the tumor remains unchallenged (Harlin et al., 
2006). This occurs through multiple mechanisms from the immunosuppression described in 
the previous sections of this chapter, and also through flaws in melanoma Ag processing, 
presentation, and costimulation. Melanoma tumors have also been shown to downregulate 
HLA class I surface expression, preventing any T cell activation and tumor clearance 
(Lopez-Nevot et al., 1988; Cabrera et al., 2007). Tumors also differentially express 
costimulatory molecules required for complete T cell activation, which will be discussed 
further in the next section of this chapter. An additional reason for the inability of CD8+ T 
cells to clear a tumor completely is that there are few to no support signals driving the anti-
tumor immune response further following the initial activation and a complete lack of 
potent antitumor immunological memory. The support signals needed are supposed to 
come from activated CD4+ effector T cells, differentiated from Tregs by their low CD25 
expression and the lack of FoxP3 (Lizee et al., 2006). CD4+ T cells release immune 
stimulatory cytokines and can directly cross present Ag to professional antigen presenting 
cells (APCs), driving a complete immune response that can lead to the development of 
immunological memory. CD4+ T are also crucial as they interact with HLA class II on 
melanoma tumors which present self tumor Ags (Figure 2). However, melanoma cells are 
severely hindered in their ability to present endogenous tumor Ags (Goldstein et al., 2008). 
Although melanoma cells can reduce their HLA class II, studies have shown that detectable 
levels of surface class II are still present that could be exploited in immunotherapeutic 
vaccine design.  
www.intechopen.com
 Treatment of Metastatic Melanoma 
 
122 
 
Fig. 2. Defects in HLA class II Ag Processing in Melanoma cells. A. Melanoma cells 
differentially process endogenous and exogenous Ags in endolysosomal compartments 
through deficiencies in Ii, HLA-DM, acidic cathepsin activity, and the failure to reduce 
oxidized peptides. This results in the presentation of a peptide milieu which fails to 
stimulate interacting CD4+ T cells, limiting the effects of CD8+ antitumor responses. B. The 
presence of GILT in endolysosomal compartments facilitates increase in both acidic 
cathepsin processing of tumor Ag and HLA class II components, and the functional 
processing of cysteinylated or oxidized peptides for improved CD4+ T cell activation. 
Melanoma cells also differentially express acidic cathepsins which catalytically process 
endogenous and exogenous Ags in endolysosomal compartments. The lack of these 
enzymes or their limited activity results in poor Ag processing and the generation of 
nonfunctional antigenic determinant(s), that when presented are incapable of stimulating T 
cells (Goldstein et al., 2008). They also express low levels of HLA-DM, a nonclassical class II 
molecule responsible for peptide loading onto HLA class II molecules and the removal of 
the class II-associated invariant chain (Ii) peptide (CLIP) (Norton & Haque, 2009). Without 
active HLA-DM function, low affinity peptides are loaded onto class II proteins and in some 
cases CLIP is not removed, the result of which is again poor immune activation (Weber et 
al., 1996). Melanoma cells also lack an important enzyme, Gamma Interferon-inducible 
Lysosomal Thiol Reductase (GILT), which is required for the functional reduction of 
cysteinylated or oxidized proteins and peptides (Haque et al., 2002). Spontaneous 
cysteinylation of peptides and Ags occurs through the formation of disulfide bonds between 
cysteine residues or when cysteine residues bind to free floating cysteine in biological fluid 
(Haque et al., 2002). These peptides display high binding affinity for the HLA class II 
binding groove, yet they are nonfunctional at CD4+ T cell activation. Figure 2 illustrates 
some of the defects in HLA class II processing and presentation utilized by melanoma 
tumors and the ability for GILT induction to improve or reverse some of these deficiencies.  
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GILT is a lysosomal reductase that is highly expressed in professional APCs, but is absent or 
expressed at low levels in melanoma (Phan et al., 2002). GILT can be induced in melanoma 
cells and in other tumor cells when treated with interferon-gamma (IFN-Ǆ) (Goldstein et al., 
2008). The expression of GILT in melanoma cells upregulates active forms of cysteinyl and 
aspartyl cathepsins such as cathepsins S, B, and D; and GILT expression also upregulates the 
non-classical class II molecule DM (Goldstein et al., 2008). GILT also breaks disulfide bonds 
within Ags/peptides providing further access for loading and processing by cathepsins 
(Goldstein et al., 2008). Melanoma cells expressing GILT may be able to efficiently process 
and present peptides to CD4+ T cells for immunological recognition and elimination of 
tumors. Unfortunately, the numerous defects illustrated here do not form the complete 
picture of melanoma immunomodulation in terms of Ag processing. Once functional 
peptides are loaded into either HLA class I or class II compartments and CD8+ and CD4+ T 
cells recognize these molecules, a second signal received from costimulatory molecules on 
the surface of the tumor is needed to activate these immune cells.  
3.2 Costimulatory molecules 
Surprisingly, melanoma tumors represent immunogenic cancers with various activation of 
antitumor immunity, yet the natural immune responses are incapable of eradicating the 
tumor, the reason for which is not fully understood (Pandolfi et al., 2008). A contributing 
factor to this is the previously mentioned immunosuppressive microenvironment and the 
altered Ag processing and presentation in melanoma that can stimulate T cells, but not in 
the same way as APCs which would drive a strong immune response against the tumor. A 
second factor influencing this inhibition is the lack of, or inhibition of, costimulatory signals 
required for optimum T cell activation. Following Ag processing and the loading of tumor 
derived peptides into the HLA class II groove, this complex is translocated to the cell surface 
for presentation to T cells. CD4+ T cells recognize functional class II complexes with 
antigenic peptides and tight junction binding occurs between the T cell receptor (TcR) and 
the class II/Ag complex (Cochran et al., 2000). CD4 molecules on T cells then bind to a 
different site on the HLA class II molecule and T cells receive their first stimulation signal 
(Chambers, 2001). A second signal is then required for activation/regulation of the T cell. If 
the T cells receive a stimulatory signal from the tumor in the form of CD80/CD86 (B7-1/2) 
binding to T cell expressed CD28, then T cells become activated and mount an antitumor 
response (Figure 3). However, costimulatory molecules are often modified on melanoma 
tumor cells inhibiting T cell activation. Melanoma tumors have been shown to express high 
levels of CTLA-4, a cell surface receptor that also interacts with CD28 but in a regulatory 
role, inhibiting T cell activation (Weber, 2008). Naturally, this function may inhibit 
autoimmune conditions, but tumors exploit this process, functionally silencing CD4+ T cell 
activation and shifting the environment to a T-regulatory setting.  
These issues are further compounded by the presence of death receptor ligands on the 
surface of melanoma tumors (Pilon-Thomas et al., 2010). T cells naturally express 
programmed death receptors (PD-1) on their cell surface as a limiting factor during T cell 
activation, sparing healthy “self” cells that may activate these T cells. TIL’s have been 
specifically shown to express higher levels of PD-1 than circulating T cells, a paradigm that 
is not completely understood (Ahmadzadeh et al., 2009). Study shows that melanoma 
tumors express high levels of the ligand for PD-1, PD-L, which during TcR-HLA interaction 
sends a death signal to both CD4+ and CD8+ T cells causing them to undergo apoptosis 
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(Pilon-Thomas et al., 2010). Melanoma specific-myeloid suppressor cells also express PD-L, 
further accelerating immunosuppression. Thus, these molecules represent ideal targets in 
developing improved melanoma immunotherapy strategies which will be discussed further 
in the following sections, particularly the use of anti-CTLA-4 monoclonal Ab (mAb).  
An additional signal worth mentioning is the much debated role of tumor FasL (CD95) 
(Hallermalm et al., 2004). FasL is a transmembrane protein belonging to the TNF 
superfamily, which when bound to its receptor induces apoptosis (Hallermalm et al., 2004). 
Multiple studies have shown melanoma tumors express detectable surface FasL expression 
both in vivo and in vitro and that this ligand may act as a first line immunosuppressor 
through inhibiting CTL activity (Shukuwa et al., 2002; Andreola et al., 2002). High surface 
FasL expression also correlates with poor disease prognosis, but whether this is due to 
enhanced immune impairment or through an autocrine tolerization against FasL-FasR 
binding remains unknown (Hallermalm et al., 2004). 
 
 
Fig. 3. Costimulatory Signals in Melanoma. A. Complete T cell activation requires binding 
between HLA class II-Ag complexes with T cell receptors on CD4+ T cells. A second signal 
between B7-1/2(CD80/86) molecules on melanoma tumors with CD28 on T cells activates 
CD4+ T cells initiating a robust immune response B. Melanoma cells differentially present 
oxidized peptides to the TcR which can inhibit T cell activation. They also express high 
levels of CTLA-4 which preferentially binds CD28 and suppresses T cell function. Blockade 
of CTLA-4 using mAb can restore immune recognition. Melanoma cells also express 
programmed death ligands (PD-L) which bind PD-1 on T cells inducing T cell tolerance. In 
addition, tumors also express surface and secretory FasL which bind FasR on T cells 
favoring apoptosis. 
Study in uveal melanoma has also shown the potential for shed FasL encapsulated in a 
microvesicle that degranulates in the microenvironment and binds to FasR expression on 
lymphocytes (Andreola et al., 2002). More research is needed to fully develop this concept, 
but the targeting of surface FasL on melanoma tumor may improve the immune 
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environment allowing immunotherapy strategies to be more effective. More effective 
targeting of these factors is also paramount in limiting disease progression before tumors 
undergo angiogenesis and eventually metastasize, which pose their own issues in targeting 
the disease. 
4. Issues with advanced disease 
The previous sections have discussed the immunological concerns with melanoma in the 
tumor microenvironment and the interplay between the tumor and the immune system. 
However, the course of tumor progression further complicates this picture as tumors 
develop microvasculature, migrate to the blood stream, and metastasize to distant sites. 
Angiogenesis is tightly linked with the vertical growth phase of melanoma; a process which 
restructures the surrounding environment allowing tumor cells to migrate to the blood 
stream. This process is accompanied by a shift in the immune environment as infiltrating 
monocytes and macrophages converge at the site of angiogenesis and are misused by tumor 
cells to further proliferate. Following angiogenesis, melanoma tumors often metastasize to 
distant and local sites contributing to the great number of melanoma associated mortality. 
Once melanoma tumors invade the vasculature and colonize distant sites, new immunologic 
dysfunction is enacted at the site, further complicating and reducing the efficacy of 
therapeutic strategies, particularly in the lymph nodes and the brain. This section will 
further examine the immunological issues presented during angiogenesis and metastasis, 
and stress the need for new techniques at targeting these processes and how it will require 
specialized immunotherapy strategies. 
4.1 Angiogenesis 
As melanoma tumors progress, there is a distinct shift from the radial growth phase to the 
vertical growth phase which is accompanied by many changes to the cellular and immune 
environment. This change is also closely linked with angiogenesis. Angiogenesis is the 
formation of new blood vessels, and is abused and unregulated in advanced melanoma 
(Mahabeleshwar & Byzova, 2007). Figure 4A shows some of the molecules involved in 
angiogenesis, and in the switch from radial growth to vertical growth in melanoma tumors. 
With the formation of new blood vessels and the vertical growth of tumors, an influx of 
immune cells occurs as a result of shed molecules like IL-8 (Waugh & Wilson, 2008).  
As previously discussed, IL-8 as well as IL-6 can act as circulating tumor cell attractants, 
which can accelerate tumor growth, angiogenesis, and recruitment of other chemo-
attractants (Kim et al., 2009). IL-8 signaling has also been shown to increase the transcription 
of nuclear factor-κB in melanoma, which may be increased through protein kinase C (PKC) 
activity (Wang & Richmond, 2001). Along with NF-κB, STAT3, and ǃ-catenin, IL-8 indirectly 
upregulates the activity of AP-1 and mTOR, which are both implicated in cell proliferation, 
invasion, and cell survival (Karst et al., 2009). VEGF is also linked with IL-8 signaling 
through its activation by the GPCR of the IL-8 receptor. VEGF is the primary molecule 
responsible for angiogenesis in both natural and melanoma settings (Srivastava et al., 2003). 
Melanoma cells have also been shown to utilize VEGF in an autocrine fashion to fuel 
progression and growth. Tumor-derived molecules like basic fibroblast growth factor 
(bFGF), placental growth factor (PGF), and platelet derived growth factor (PDGF) aid in 
melanoma angiogenesis, and may represent potential targets in immunotherapy design 
(Figure 4). Other angiogenic factors involved in melanoma are the matrix metalloproteinases   
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Fig. 4. Angiogenesis and Metastasis in Melanoma. A. Extracellular restructuring molecules 
are shed by both metastatic tumors and infiltrating bystander cells. These molecules (VEGF, 
PGF, FGF-2, and MMPs) lead to increased cell-cell contact, movement, and vascularization. 
The transition into vertical growth phase is then accompanied by increased autocrine IL-8 
signaling which supports angiogenesis through recruitment of tissue destabilizing 
molecules and immune cells. Urokinase plasminogen activator and its receptor 
(uPA/uPAR) further angiogenesis by promoting cell movement and reorganization of 
endothelial cells into tube-like structure allowing tumors to reach the blood stream. B. 
Following RGP and VGP tumors metastasize to colonize distant sites such as sentinel lymph 
nodes, the lungs, liver and brain by entering the blood stream or through the lymphatic 
network. Within lymph nodes further immune suppression is induced through high levels 
of T regs, IL-10, and immature DC. 
(MMPs). MMPs are a large group of secreted proteases that are involved in normal 
physiological and pathologic processes such as embryogenesis, wound healing, 
angiogenesis, tissue remodeling, tumor invasion, and metastasis (Kondratiev et al., 2008). 
Within this family of proteins, MMP-2, MMP-9, MMP-13, and MMP-14 have been found in 
melanoma, and are used as biomarkers for staging (Bosserhoff, 2006; Beshir et al., 2010). MMP-
2 and MMP-9 degrade connective tissue and basement membrane collagen, and are believed 
to play an important role in skin and uveal melanoma progression (Kondratiev et al., 2008; 
Seftor et al., 2001). During the utilization of these molecules and others, there is localized 
inflammation occurring with the influx of lymphocytes, monocytes and macrophages. These 
cells are then activated and secrete TNF-ǂ and IL-1 ǂ in response to the shed VEGF and IL-8, 
which tumor cells then use in furthering their proliferation (Moldovan, 2002; Moldovan & 
Moldovan, 2005). In this system, the inhibition of macrophage/monocytes activation could aid 
in limiting tumor progression and angiogenesis. In an expert review of angiogenesis in 
melanoma, Ria et al describe the complete angiogenic process, the molecules involved, and the 
strategies designed to target these factors (Ria et al., 2010). The targeting of these molecules 
and the inhibition of the pro-tumorigenic influx of immune cells should aid in improving 
melanoma immunotherapy strategies. 
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4.2 Metastasis  
Following melanoma angiogenesis and the vertical growth of melanoma into localized 
blood vessels, tumors metastasize to multiple distant sites including lymph nodes, the liver, 
lungs and brain (Streit & Detmar, 2003; Zbytek et al., 2008). This process has often occurred 
by the time melanoma is detected clinically, further complicating the treatment of the 
disease (Murakami et al., 2004). The first site of tumor metastasis is often the sentinel lymph 
node, which also serves as an important prognostic marker of melanoma progression 
(Takeuchi et al., 2004; Streit & Detmar, 2003). This progression to sentinel lymph nodes is 
closely related with angiogenesis, as these sites in metastatic melanoma patients have high 
expression of VEGF molecules (VEGF-C and VEGF-D) providing the link from tumor 
progression to metastasis. This process is also further driven by chemoattractive activity of 
tumor associated lymphatic endothelial cells which may act to draw melanoma cells to the 
lymph node (Kakinuma & Hwang, 2006; Streit & Detmar, 2003). This activity is a natural 
means of attracting mature dendritic cells to sentinel lymph nodes, but some melanoma 
tumors express the same surface receptor (CCR7) as dendritic cells, and are mistakenly 
drawn to the lymph nodes (Murakami et al., 2004). This is interesting, as targeting this 
surface receptor may aid in the prevention of melanoma metastasis.  
The deregulated immune environment is also responsible for the spread of melanoma 
tumors from tissue to lymph nodes. The highly immunogenic nature of melanoma and the 
manipulation of immune cells by tumors, particularly in the development of Tregs, could 
contribute to the movement to sentinel lymph nodes. Within these lymph nodes, melanoma 
tumors further suppress the influx of anti-tumor immune cells through the tolerization of 
DC and the large number of Treg cells accompanying the tumor (Figure 4B) (Shu et al., 
2006). As described in the immune cell section of this chapter, these Treg cells in the lymph 
are now capable of more widespread suppression allowing for the colonization of distant 
sites by travelling through the lymphoid network as veritable ”body guards” surrounding 
the tumor. Tumors are also capable of traveling through the vascular network to colonize 
distant sites, which requires surviving the vascular environment, adhering to the desired 
organ, and invading the desired tissues. These processes are accomplished through 
upregulation of adhesion molecules on melanoma tumors like integrins allowing for 
adhesion and passage into distant tissue (Yoshimura et al., 2009).  
Melanoma tumors now metastasize to distant sites including the liver, lungs, and brain. 
Single solitary tumors are effectively cleared through surgery, but multiple metastatic 
lesions limit surgeries effectiveness. The involvement of major organs represents a sharp 
decrease in the efficacy of treatment options, and with respect to brain metastasis, accounts 
for the overwhelming majority of melanoma deaths (Zbytek et al., 2008). Liver metastasis is 
often seen in cases of uveal melanoma and is treated through chemotherapy and surgery 
(Vahrmeijer et al., 2008). Unfortunately, unlike other cancers that metastasize to the liver, 
melanoma metastasis often cannot be resected due to the gross number of tumors and the 
location of the tumor (Vahrmeijer et al., 2008). Melanoma tumors which metastasize to the 
lungs often pose the same problems that liver metastases do, in which surgical resection is 
often impossible, and, to compound problems, brain metastases are often concurrent with 
lung metastasis, though the lungs are probably colonized first (Fidler et al., 1999). In these 
unique cases immunotherapy may be considered in place of or in conjunction with 
chemotherapy. A recent in vitro study on preferential liver metastasis of melanoma showed 
a correlation between the presence of high integrin 2ǂ on invading tumor cells versus those 
that did not metastasize to the liver (Yoshimura et al., 2009). Targeting this surface molecule 
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through the use of a monoclonal antibody could then prove useful in inhibiting disease 
before it progresses to the liver. Lung cancer can pose additional concerns; airway passage 
epithelial cells, like those found in the lungs, can possess TLR2 surface expression, which in 
vitro study has shown to be upregulated in metastatic melanoma cell lines (Yang et al., 
2009). TLR2 activation can promote an influx of lymphocytes and cytokine production 
through STAT3 regulated pathways, which we have already mentioned, are deregulated in 
cases of melanoma. This same study showed that inhibiting TLR2 through the use of an 
anti-TLR2 antibody inhibited the extent of pulmonary melanoma metastasis, a concept 
which could prove useful in devising novel immunotherapy strategies (Yang et al., 2009). 
Despite brain metastasis resulting in the majority of melanoma deaths, relatively little is 
known about the processes involved in brain metastasis (Sloan et al., 2009). Patients with 
multiple melanoma brain lesions have few treatment options. When 1-3 brain metastases are 
present, surgery and stereotactic radiosurgery are routinely performed, but when more 
metastases are present surgery loses efficacy and response rates to chemotherapy remain 
low (Sloan et al., 2009; Aboody et al., 2006). Unfortunately, the presence of brain metastasis 
was often used as an exclusion criterion for immunotherapy trials of metastatic melanoma. 
Some studies using both biological response modifiers like IL-2/IFNǂ and cellular 
immunotherapy employing MART-reactive TIL’s have shown some success (Sloan et al., 
2009). Given the ability for some immune passage through the blood brain barrier, 
immunotherapy should be on the forefront of treatment for melanoma brain metastases, yet 
clinical manifestations of successful immunotherapy remain limited (Sloan et al., 2009).  
5. Issues with immunotherapy 
In many ways, melanoma represents the gold standard in immunotherapy design and 
clinical application. Melanoma is a highly immunogenic tumor, and clinical evidence has 
shown spontaneous regression of primary lesions in a significant number of tumors 
(Komenaka et al., 2004). This should not be confused with the outlined immunomodulation 
and immune deficiencies outlined in this chapter, melanoma tumors still evade immune 
clearance and detection, particularly in advanced metastatic disease. The study of melanoma 
immunotherapy has existed in some form for the last 30 years, with some major 
breakthroughs to show for all this hard work (Weber, 2011). In general, immunotherapy 
refers to any therapeutic intervention designed to stimulate, inhibit, support, or alter the 
immune system as a means of inducing tumor destruction. Immunotherapy strategies 
include the use of immunostimulatory cytokine administration like IL-2 and IFNǂ, adoptive 
cell transfer (ACT), multiple cancer vaccination strategies, and the use of monoclonal 
antibodies which target tumor Ag or suppress melanoma derived inhibitory signals (Weber, 
2011). Some of the strategies used in a clinical setting are highlighted in Table 2. 
Surprisingly, with all of this work done, only recently has an immunotherapy shown a 
survival advantage in patients with advanced disease (Hodi et al., 2010). This section will 
briefly highlight some of the successes and issues with current immunotherapy, and try to 
determine how these deficiencies may be overcome. A more complete review of melanoma 
immunotherapy strategies can also be found from Sivendran et al (Sivendran et al., 2010). 
The first immunotherapy strategies to show clinical promise were the immune stimulating 
cytokines IFNǂ and IL-2, both receiving FDA approval for the treatment of melanoma in the 
1990’s, IFNǂ in the treatment of stage III melanoma with Decarbazine and IL-2 in stage IV 
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. 
Name Action Approval status Clinical results Issues
IFN-┙
(IFN-┙2┚, PEG-IFN)
Activates and 
stimulates DC and T 
cells, while  cytotoxic to 
melanoma through 
STAT1 activation and 
STAT3 
downregulation.
1995, As adjuvant with 
surgery or cytotoxic 
chemotherapy, most
notably dacarbazine.
10-15% response rate,  
useful in cases of 
limited disease.
As single agent, high 
toxicity profile, 
adjuvant therapy has 
been linked with 
psychiatric issues like 
depression and mania. 
IL-2
(Proleukin)
Expands and activates 
T cells, administered in 
bollus high dose.
1998, Stage IV 
melanoma.
15% response rate, 
some patients having
durable responses to 
treatment, when in 
high dosage treatment 
regimen.
High toxicity profile. 
Best results only seen in 
a small inclusion group 
with limited disease 
progression and 
minimal organ 
involvement.
Canvaxin
(onamelatucel-L)
Antigen-rich, allogeneic 
whole-cell vaccine.
Phase III trials ended in 
2005 due to inefficacy.
Initial clinical trials 
were promising 
showing increased 
overall survival gains 
of 19 %and 12% in 
stage III and IV 
melanoma respectively.
During phase III 
clinical trails an  
independent safety 
reviewed board reveled 
Canvaxin was no more 
effective than control 
arm.
Adoptive cell therapy
(ACT-CTL or ACT-TIL 
therapy)
Patient PBMCs are 
pulsed in vitro with 
melanoma peptide/Ag 
or stimulatory 
cytokines and CTL 
clones are isolated, 
expanded and injected.
Ongoing clinical trials
using pretreatment of 
lymphodepletion
through irradiation or 
chemotherapy prior to 
ACT  injection.
Response rates have 
been reported as high 
as 50%, particularly in 
large bulk tumor cases  
when following 
lymphodepletion .
Lymphodepletion
required for efficacy, 
but all patients can’t 
tolerate 
Ontak
(DAB/IL-2, Denileukin
Diftitox)
Recombinant IL-
2/diptheria toxin 
conjugate binds to IL-
2R expressing cells 
depleting these 
lymphocytes.
Currently in Phase II 
clinical trial as 
intervention.
Promising results from 
phase II trials where 
lymphodepletion was 
observed with the 
formation of anti-
melanoma CD8+ T 
cells.
While it depletes 
detrimental T reg cells, 
CD8+ and CD4+ 
effector cells are also 
depleted limiting 
overall efficacy.
 
Table 2. Issues Associated with Various Melanoma Immunotherapy Strategies 
disease (Fang et al., 2008). IL-2 therapy remains the only immunotherapy strategy for late 
stage melanoma but significant issues remain with its use. IL-2 therapy displays moderate to 
severe toxicity and relatively low efficacy in patients with non-cutaneous metastasis and 
metastatic organ involvement (Petrella et al., 2007). Thus, the key to improving IL-2’s use in 
a clinical setting is in the selection of patients receiving treatment. Younger patients who are 
in good health, with little to no organ metastasis would see the most benefit from IL-2 
therapy, and patients with stage II/III tumors may see even greater response to this 
treatment. Similarly, IFNǂ displays toxicity similar to cytotoxic drug therapy and this 
toxicity increases greatly when administered over longer periods of time. Some study also 
showed a correlation between IFNǂ and clinical manifestations of depression, mania, and 
suicidal tendencies (Greenberg et al., 2000). The cause behind these effects is poorly 
understood, but will remain a concern to monitor with IFNǂ therapy moving forward. 
However, the main concern with IFNǂ is the lack of improvement in overall survival, with 
only transient gains seen in relapse-free survival (RFS) (Kirkwood et al., 2004). Efforts to 
combine IFNǂ with a cancer vaccine strategy were disappointing, but seem to reflect issues 
in the design and selection of the melanoma vaccine (Kirkwood et al., 2004). The use of IFNǂ 
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to boost an antitumor response paired with an effective vaccine or with ACT could still 
prove beneficial and shouldn’t be ruled out in therapeutic design. 
Another very promising concept in immunotherapy design which has failed to aid in the 
clinical setting is melanoma cancer vaccines. These can come in the form of whole cell cancer 
vaccines, tumor cell lysates, protein/peptide vaccines, DC loaded vaccines, viral vectors, 
and DNA vaccines (Terando et al., 2007). To date, the largest phase III melanoma vaccine 
clinical trial involving late stage III and IV melanoma compared the use of CanVaxin with 
the nonspecific immune stimulator Bacillus Calmette-Guerin (BCG) or BCG alone (Morton 
et al., 2002). BCG is currently being evaluated in phase III clinical trial administered 
following surgery versus best standard medical care alone in patients with advanced 
metastatic disease. CanVaxin is an allogeneic whole cell cancer vaccine using three of the 
most widely studied melanoma cell lines which encompassed a vast pool of Ag targets and 
showed great promise during phase II clinical trials. 
Unfortunately, an independent safety review board halted the phase III trial when evidence 
showed no detectable advantage in the treatment arm, virtually stopping CanVaxin in its 
tracks (Eggermont, 2009). A key issue with the design and application of CanVaxin could be 
the lack of host Ag presented in the vaccine, given differences between the tumor cell lines 
used versus the primary tumor. Studies utilizing host-derived irradiated tumor cells instead 
of cell lines, have shown immune reactivity and limited toxicity, but the time required for 
their generation remains a concern. These cancer vaccine strategies have been investigated 
in early clinical trials but the clinical manifestation of strong antitumor T cell activation 
remains elusive (Goldman & DeFrancesco, 2009). Some efforts to improve the design and 
application of these vaccines will be further discussed in the next section. 
Currently, an immunotherapy strategy with the potential for success is adoptive cell therapy 
(ACT). As previously mentioned, the highly immunogenic nature of melanoma tumors 
generates large pools of melanoma reactive CD8+ T cells in vivo, which can be extracted and 
expanded in vitro. This expansion of patient lymphocytes can be done through stimulation 
with T cell growth factors like IL-2 or through stimulation with melanoma tumor Ags 
(Rosenberg et al., 2003). Following expansion, these T cells are then reinjected into patients 
to attack the tumor. This method has resulted in durable response rates, particularly in stage 
II/III patients; and in some cases, complete tumor reduction (Rosenberg et al., 2003). 
However, trials in late stage melanoma failed to show durable tumor clearance, most likely 
due to the high percentage of Treg cells and immunosuppressive cytokines in the 
microenvironment (Rosenberg et al., 2008). To combat this, the combination of 
lymphodepletion with chemotherapy or radiation prior to reinfusion of T cells can greatly 
improve the response to treatment (Dudley et al., 2008). Unfortunately, lymphodepletion in 
itself is hazardous to the patient as it destroys both the antitumor CD8+ and CD4+ effector 
cells along with the Treg cells, and leaves patients vulnerable to bacterial and viral infections 
(Dudley et al., 2008). Agents capable of specific Treg depletion would aid ACT therapy 
greatly, and a few molecules in clinical trials potentially fit this need. Ontak (Denileukin 
Diftitox), a recombinant fusion protein combining IL-2 with Diptheria toxin, binds to IL-2R 
expressing cells and induces apoptosis through toxin release. It has been shown to deplete 
Treg cells, resulting in a CD8+ antitumor response in phase II clinical trials (Mahnke et al., 
2007). However, CD4+ effector cells were also depleted following Ontak administration, a 
potentially limiting factor in the long term durable anti-tumor response. The combination 
then of Ontak with ACT could improve the efficacy of immunotherapy in advanced disease 
patients, but an important aspect of immune stimulation remains absent from this 
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therapeutic design: the activation of CD4+ effector T cells. As mentioned previously, CD4+ 
T cells play an important role in anti-tumor immunity particularly in the presentation of 
tumor Ags to professional APCs and CD8+ T cells, and in the induction of long-lasting anti-
tumor immunological memory (Hung et al., 1998). Therefore, future strategies should aim to 
activate both CD4+ and CD8+ T cells in ACT therapy design, an idea which will be further 
explored in the following section. 
6. Potential new directions 
As highlighted in the previous section, our lack of success in melanoma immunotherapy is 
not for a lack of effort. With the last thirty years of immunotherapy design and clinical trials 
we can now apply what we’ve learned to novel ways of addressing the complex problem of 
metastatic melanoma. This may include revisiting some previously attempted ideas, but 
applied within a new context, particularly with what we know about the localized immune 
inhibition in melanoma patients. This section will discuss current strategies being developed 
and potential new directions in treatment that address the immunomodulatory nature of 
melanoma. These include novel chemoimmunotherapy ideas and techniques, the further use 
of monoclonal antibodies against melanoma Ags and T cell inhibitory factors and finally, on 
how combining multiple approaches in multimodal immunotherapy design represents a 
fight on multiple fronts with the potential for increased tumor destruction and disease free 
survival.  
6.1 Chemoimmunotherapy 
Therapeutic approaches combining cytotoxic chemotherapy with immunotherapy is not a 
new concept by any means  (LoRusso et al., 1990). In fact, both IFNǂ and IL-2 have been 
extensively tested in combination with chemotherapeutics like decarbazine (DTIC), 
temozolamide, and cisplatin (Schadendorf et al., 2009). Yet, only the pegylated (PEG)-IFNǂ 
+ DTIC or PEG-IFNǂ + temozolomide showed enhanced response rates, and all other trials 
failed to show any significant survival rates (Schadendorf et al., 2009). Moreover, the 
combination of these molecules increased overall toxicity greater than individual treatment, 
another limiting factor in the use of combined chemoimmunotherapy (Schadendorf et al., 
2009). However, these results only indicate that the combination of two highly cytotoxic 
agents with limited efficacy in their own right are incapable of enhancing patient survival in 
highly advanced stages of diseases. Similar approaches should be carefully studied and 
considered in patients with diminished risk who demonstrate high tolerability to treatment, 
like the concession currently made for those receiving high dose IL-2 therapy. In selecting 
the right patient for this therapy, considerable gains may still be made in the combination of 
these agents. A second approach may be to limit the toxicity of the chemotherapeutic and 
select a drug with immunostimulatory properties. These molecules may include the highly 
en vogue antioxidant molecules like green tea extracts, holistic mushroom extracts, and 
flavinoids, each displaying cytotoxicity in tumor models in vitro with limited toxicity to 
healthy cells (Baliga & Katiyar, 2006; Harhaji Trajkovic et al., 2009; Craig, 1999). More 
importantly, these molecules may work synergistically with immune stimulating molecules 
through enhanced immune activation (Banerjee et al., 2008). Extensive research needs to be 
performed to ensure similar results in vivo as displayed in vitro, but the combination of 
these more tolerable antitumor agents with immunostimulatory cytokines may generate 
increased tumor clearance while reducing the toxic burden to individuals. Similarly, altering 
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the immune cytokine used could aid in the efficacy and reduced toxicity of 
chemoimmunotherapy.  
Cytokines like IL-15, IL-7, and IL-21 could prove more beneficial in stimulating antitumor 
immune cells during chemotherapy, with reduced toxicity when compared to IL-2 or IFNǂ 
(Epardaud et al., 2008; Ribas, 2006). IL-21 has the added benefit of more selective T cell 
expansion versus IL-2, in which Tregs are not responsive to IL-21 stimulation (Sivendran et 
al., 2010). Currently IL-21 is being tested in phase I/II clinical trials displaying promising 
results (Sivendran et al., 2010). IL-15 shares similarity with IL-2 through a shared receptor 
subunit, but IL-15 has been shown to enhance both ACT and chemotherapy strategies in 
mouse models with almost no cytokine associated toxicity (Epardaud et al., 2008). Current 
research performed using IL-15 preconjugated with its receptor (IL-15ǂ) increased both the 
half life and activity of the cytokine, and improved its ability to destroy advanced solid 
tumors (Epardaud et al., 2008). Though preliminary, this discovery could prove beneficial in 
the use of cytokine therapy as both single agent, and in combination with 
chemotherapeutics to more effectively destroy melanoma. An additional strategy for 
combined chemoimmunotherapy use is in cancer vaccination design and application. In this 
case, chemotherapy prior to or concurrent with peptide or DC loaded vaccine techniques 
could allow for improved efficacy of a single treatment alone. Unfortunately, clinical trials 
have yet to show significant advantages to combining cytotoxic therapy with vaccine 
strategies over chemotherapy alone (Lens, 2008). To address this issue, study should 
incorporate drugs which target progression or metastasis of melanoma in conjunction with 
immunotherapy as a means of limiting tumor movement and increasing the chances of 
immune induced tumor clearance. As previously mentioned, Ria et al describe multiple 
anti-angiogenic drug candidates which could halt the progression of tumors through 
inhibiting VEGF, VEGFR, tyrosine kinase receptors, integrins, and MMPs (Ria et al., 2010). 
Combining these inhibitors with immune vaccines to stimulate antitumor immunity or with 
ACT could allow the reduction of both localized and metastatic tumors.  
Currently, the most beneficial chemoimmunotherapy strategy uses lymphodepleting 
chemotherapeutics (cyclophosphamide and fludarabine) prior to reinjection with expanded 
TILs and high dose IL-2. This strategy vastly improves the response rate and efficacy of ACT 
through depletion of Tregs allowing for greater TIL expansion in vivo following reinjection. 
Unfortunately, lymphodepletion leaves the patient susceptible to both bacterial and viral 
infection, and is not specific for Tregs; all supportive anti-melanoma CD8+ and CD4+ T cells 
are also destroyed in the process. Treg-specific reduction prior to ACT represents the gold 
standard of improved treatment, yet as described previously our best efforts using drugs 
like Ontak are still shy of clinical relevance (Mahnke et al., 2007). Increased effort needs to 
be placed on developing Treg specific lymphodepleting chemotherapy, allowing for the full 
effect of ACT to show clinical benefit. These improvements to chemoimmunotherapy design 
are not the only potential new directions in melanoma therapy; the most promising option 
in the near future appears to be the use of monoclonal antibodies in the fight against 
advanced disease. 
6.2 Monoclonal antibodies 
Monoclonal antibodies (mAb) have been the focus of much research in cancer since their 
discovery some thirty plus years ago (Oldham & Dillman, 2008). Though some mAb have 
been approved to treat other cancers, most notably Trastuzumab (Herceptin) in the 
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treatment of breast cancer, there is only one FDA approved mAb for the treatment of 
advanced melanoma, ipilimumab (Dillman, 2011). Ipilimumab is one of a number of mAb 
designed to selectively block CTLA-4 activity in melanoma tumors allowing for the 
expansion and activation of CD8+ and CD4+ anti-melanoma T cells (Robert & Ghiringhelli, 
2009). This chapter previously described the effect high CTLA-4 expression has on 
melanoma tumors by inhibiting the costimulatory signal needed for T cell activation, 
shifting the immune response from active to suppressive. Ipilimumab has been tested in 
clinical trials both as a single agent and in combination with chemotherapy and vaccine 
strategies (Wolchok et al., 2010; Weber et al., 2009). Recent phase III clinical trials of 
advanced disease showed, for the first time, a significant survival advantage of patients 
treated with ipilimumab versus a gp100 vaccine alone, representing a huge breakthrough in 
these advanced disease patients (Hodi et al., 2010). A larger phase III comparison study 
using DTIC ± ipilimumab involving more than 500 patients has been performed, the results 
of which led to the approval of Ipilimumab in the treatment of advanced melanoma on 
March 25, 2011. Ipilimumab, like any other treatment, is not without issue, as patients 
undergoing treatment have experienced immune-induced side effects including dermatitis, 
enterocolitis, hepatitis, and most significantly diarrhea (Sivendran et al., 2010). Some 
interesting treatment effects have also been observed in a number of patients treated with 
ipilimumab which will require close attention in determining the best treatment protocol. A 
number of patients receiving ipilimumab displayed delayed slow ongoing responses lasting 
a year or more, delayed responses taking up to 6-12 months, and surprisingly, tumor 
growth and progression followed by tumor regression (Weber, 2011). These interesting 
effects could lead to the withdrawal from treatment due to the appearance of tumor growth 
or the delayed response, but these patients need to remain in treatment as the patients who 
displayed these characteristics often had better disease prognosis than others (Weber, 2011). 
New immune criteria for the judgment of drug efficacy should be included in determining 
the best course of patient treatment to avoid issues like these, particularly as ipilimumab has 
great potential as a combined agent with vaccination and cytotoxic drug therapy, and most 
interestingly with ACT.  
Ipilimumab is not the only mAb targeting advanced disease receiving clinical attention; anti-
PD-1, anti-CD137, and anti-CD40 are all undergoing clinical investigation (Sivendran et al., 
2010). Anti-PD-1 has shown promise in melanoma cell lines and small phase I/II clinical 
trials displayed immune activity without major drug associated toxicity, opening the door 
for its use in combination with other mAb and immunotherapeutic strategies (Brahmer et 
al., 2010). Clinical trials are ongoing, pairing anti-PD-1 with CTLA-4 blockade or with 
multiple melanoma peptide vaccine strategies (Curran et al., 2010). Anti-CD137 binds to 4-
1BB expressed on activated immune cells sending a costimulatory signal promoting 
lymphocyte activation (Meseck et al., 2011). In trials using anti-CD137 with GM-CSF-
secreting tumor cell immunotherapy induced complete rejection of tumor in a B16 mouse 
model, displaying proof of principal in melanoma immunotherapy use (Li et al., 2007). 
Results of a phase I clinical trial revealed antibody activity associated with minimal toxicity 
in patients with advanced solid-tumor malignancies (Sivendran et al., 2010).  
Similarly, anti-CD40 binding with CD40 on the surface of immune cells results in the 
activation of T cells, and the upregulation of MHC class II complexes and costimulatory 
molecules, two characteristics we have previously described as being major roadblocks to 
immunotherapy of advanced melanoma (Law & Grewal, 2009). Anti-CD40 has been tested 
in advanced solid tumors, refractory Hodgkin lymphoma, and multiple myeloma (French et 
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al., 1999). In melanoma, anti-CD40 seems ideal for combination with protein/peptide 
vaccine strategies as upregulation of MHC class II complexes and costimulatory molecules 
would increase the amount of tumor-vaccine interaction and presentation to T cells where 
increased costimulatory molecules would promote T cell activation instead of suppression 
or T cell anergy. Future efforts in melanoma mAb design should include the targeting of 
immunosuppressive cytokines and molecules like those outlined at the start of the chapter 
as a novel mechanism of enhanced immune activation. These molecules include, but are not 
limited to, IL-10, TGF-ǃ, PGE2, IDO, and VEGF. Through the targeting and inhibition of 
these molecules a more immunosupportive tumor microenvironment could increase the 
efficacy of current and future immunotherapy strategies. Along with cytokine therapy, the 
use of mAbs in the treatment of metastatic melanoma appear to have the fastest course to 
clinical use, but the ideal immunotherapeutic strategy would combine these techniques with 
ACT or vaccination strategies, promoting long-term, sustained immunological anti-tumor 
responses. 
6.3 Multimodal therapy strategies 
As outlined in this chapter, melanoma tumors deploy multiple immune evasion techniques 
to subvert both natural and therapy induced anti-melanoma immune responses, despite the 
highly immunogenic nature of melanoma tumors. It should then make logical sense that 
targeting one of these pathways or suppressive mechanisms would incompletely abrogate 
the problem, as different mechanisms would take over the immunomodulatory duties of 
melanoma tumors inhibiting the treatments efficacy. Thus, strategies to target melanoma 
should target multiple suppressive pathways preventing tumors from avoiding single agent 
strategies. This is accomplished by the administration of multimodal therapy design, in 
which the combination of therapies enhances the effectiveness of each individual therapy 
increasing the durability and intensity of the anti-tumor response (Kudo-Saito et al., 2005). 
Multiple in vitro and melanoma mouse models support the notion of multimodal therapy as 
a way to completely ablate tumor burden and prevent its recurrence (Ascierto et al., 2010). 
Clinically, the combination of strategies is not a new method by any means, and even 
current immunotherapy techniques often combine chemotherapeutic agents with immune 
cytokines and mAbs for improved treatment (Bhatia et al., 2009). However, in moving 
forward in the design of improved melanoma therapy, combining multiple immunotherapy 
strategies like, ACT, gene therapy, DC or peptide vaccines, cytokine therapy, mAb therapy, 
and novel tumor molecule targeting could represent the future standard of advanced 
melanoma therapy. Before this ideal can be realized, there are some issues with each 
technique individually that need to be fixed prior to their combination. Some of these issues 
we have already mentioned: the inherent toxicity of immune stimulatory cytokine like IL-2 
and IFNǂ, the failures of ACT to fully stimulate long-term anti-tumor immunity, the time 
required in generating an expanded pool of TIL for ACT therapy, and the inefficacy of 
vaccine strategies in vivo like those seen with CanVaxin (Berinstein, 2009). The first two 
issues we have already addressed; the use of less toxic cytokines like IL-7, IL-15/IL-15R, and 
IL-21 could alleviate toxicity concerns while promoting the expansion of activated immune 
cells, particularly those which promote immunological memory, and through 
lymphodepletion prior to ACT expanded lymphocytes are capable of repopulating the 
immune environment with anti-tumor CD8+ T cells leading to longer efficacy (Dudley et al., 
2008). The last two issues are more difficult to solve, but there is hope on the horizon.  
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The effect that melanoma has on the immune system both hinders our ability to treat the 
disease, and also allows for treatment like ACT to effectively kill tumors due to the 
immunogenic nature of melanoma. Unfortunately, only about 50% of melanoma patients 
have TILs capable of being expanded in vitro for reinjection, a number still much higher 
than in other cancers where the feat is near impossible (Rosenberg et al., 2008). Further 
complicating things, the generation of expanded activated TILs takes a few weeks, during 
which, valuable treatment time is lost for those patients with advanced disease, and with 
lymphodepletion the chances of an infection increase greatly (Rosenberg et al., 2003). Thus, 
the ability to expand activated patient TILs from all patients and the rapid generation of 
anti-tumor lymphocytes would further the effectiveness and clinical application of ACT 
(Rosenberg, 2001). To achieve this, rapid selection of CD8+ T cells with characteristics 
predetermined beneficial for anti-tumor immunity can be separated in culture and 
expanded with administration of anti-CD3 and the presence of feeder cells to increase the 
activation and expansion rate. Results from this treatment manipulation have shown benefit 
over previous strategies (Rosenberg et al., 2008). To combat the inability of all patients to 
generate active TIL, strategies which clone TcRs from activated TIL population into 
peripheral blood mononuclear cells (PBMCs) of melanoma patients allows for the reinjection 
of primed anti-tumor lymphocytes without the need for expanded TILs (Weber, 2011). An 
additional benefit of cloning in these TcRs is that they can be manufactured to express 
theoretically any melanoma Ag capable of synthetic production, improving the chances of T 
cell stimulation in vivo through cross-presentation (Robbins et al., 2011). Study using this 
method has shown benefit in a number of cancers, even in the absence of prior 
lymphodepletion, further reducing treatment associated toxicity (Robbins et al., 2011).  
An additional strategy which should be explored is the expansion of CD4+ effector TIL in 
the same fashion as CD8+ CTL for combined ACT capable of a more prolonged interaction 
resulting in increased tumor clearance. These CD4+ TIL can be expanded and raised against 
patient derived or synthetically generated melanoma Ag, allowing for direct cross-
presentation with patient lymphocytes in vivo. This could then lead to the development and 
support of CD8+ memory T cells, as long as the synthetic Ag is highly immunogenic and 
replicates the immunodominant HLA matched tumor epitopes. This last point, the ability to 
present synthesized melanoma Ag capable of stimulating patient immune cells in vivo is 
also a major issue in vaccine development. As previously mentioned, melanoma vaccine 
strategies are as varied as they are disappointing in the clinical setting facing issues of 
inefficacy, inferiority to chemotherapy, and a failure to work in collaboration with other 
techniques (Berinstein, 2009). Two key issues face melanoma vaccine strategies, the selection 
of immunogenic tumor associated Ags and the reliance on only CD8+ CTL stimulation in 
vaccine design, and in many ways these two problems go hand in hand (Sondak et al., 2006). 
In this chapter, we have highlighted the importance of stimulating CD4+ effector T cells in 
developing a robust immune response through cross-presentation to CD8+ T cells and other 
APC, but also for their release of immunostimulatory cytokines like IFNǄ (Corthay et al., 
2005). Yet, until recently, vaccine strategies (protein/peptide, whole cell, or DC loaded 
vaccines) have solely used tumor Ags designed for CD8+ CTL activation (Terando et al., 
2007). Though these T cells are responsible for the bulk of tumor destruction, time and time 
again they fail clinically to eradicate host tumors, often due to induced T cell tolerance 
against these Ags propagated by tumors (Terando et al., 2007). Only through the discovery 
and application of HLA class II specific anti-tumor melanoma Ags, effector CD4+ T cells 
may get the much needed stimulation required for a complete T cell response.  
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Excellent work has been done in the field of HLA class II specific melanoma Ags in recent 
years, specifically in the identification of an HLA-DR4 restricted Melan-A/Mart-151-73 
epitope (RNGYRALMDKSLHVGTQCALTRR) capable of stimulating CD4+ anti-tumor T 
cells in a number of DR matched patients (Zarour et al., 2000). The identification of Ags like 
these should be added to patient specific vaccine strategies matching both HLA class I and 
HLA class II allele specific immunogenic Ags in order to improve the efficacy of melanoma 
tumor vaccines. A second vaccine strategy which stimulates both CD8+ and CD4+ T cells 
utilized a natural process of HLA class II peptide presentation in a whole cell cancer vaccine 
design for enhanced Ag-T cell interaction (Bosch et al., 2010; Thompson et al., 2008). This 
class II vaccine uses tumor cells genetically modified to express surface class II and 
costimulatory molecules without expressing invariant chain (Ii). As previously described, Ii 
blocks the loading of antigenic peptides into the HLA class II peptide binding groove prior 
to presentation in the endolysosomal compartments (Thompson et al., 2008). By silencing Ii, 
numerous novel class II peptides are loaded onto the HLA binding groove which would 
have normally been blocked (Thompson et al., 2008). These peptides may or may not be 
functionally active, but they do represent peptides which T cells are not tolerant against, 
allowing for potential T cell activation. The presence of costimulatory molecules on the 
vaccine-cell surfaces furthers the chance of immune activation, as T cells receive the support 
signal needed for activation. A third way to generate novel immunogenic peptides for HLA 
class II presentation, which has been briefly stated, is the induction of GILT into whole cell 
vaccine strategies. GILT has been shown to increase HLA-DM expression, cysteinyl protease 
activity, and functionally reduces cysteinylated or oxidized Ags/peptides when transfected 
into melanoma cells (Goldstein et al., 2008; Rausch et al., 2010). In much the same fashion as 
the previously described vaccine design, GILT’s presence could generate novel 
immunogenic tumor Ags capable of stimulating CD4+ T cells in vivo. Though early in 
discovery, techniques like these should be pursued in the improved design of melanoma 
cancer vaccines. The combination of these improved techniques, with those already 
described, in a multimodal immunotherapeutic design could then provide the most benefit 
in terms of long-term tumor free survival. A proposed outline of a multimodal 
immunotherapy regime is shown in Figure 5. 
By first clearing the Tregs from the tumor microenvironment, any immunotherapy strategy 
will see improved efficacy, similar to those seen in ACT clinical trials (Dudley et al., 2008). 
ACT TIL therapy utilizing both CD4+ and CD8+ activated and expanded T cells or through 
the addition of TcR-Ag specific transfected PBMCs are then free to repopulate the immune 
environment. TIL responses against the tumor should then sustain for much longer than 
previously observed with the addition of activated CD4+ T cells using HLA class II specific 
tumor Ags and with concurrent stimulation with mAb against CTLA-4. The patient should 
then be monitored for response to treatment seen in tumor reduction and by extracting a 
sample of patient TILs checked for tumor reactivity. The addition of an improved DC 
loaded vaccine pulsed with processed tumor peptide-GM-CSF fusion protein, like those 
used in the successful prostate cancer therapeutic Sipuleucel-T (Provenge), could then act as 
a boost to the anti-tumor TILs present sustaining the development of immunological 
memory (Brower, 2010). Finally, using less toxic cytokine therapy through IL-15/IL-15R or 
with IL-7, IL-21 will support the continuation of CD8+ memory T cells and fuel the 
remaining anti-tumor lymphocytes into attacking the tumor. Though complex, the 
combination of these procedures would more effectively target the multiple 
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Fig. 5. Multimodal Therapy Design. A. Most of not all immunotherapy strategies should 
include a means of Treg depletion to prime antitumor immune responses. B. This may come 
in the form of an adoptive cell therapy (ACT) using autologous TIL’s expanded in vitro and 
pulsed with tumor specific peptides targeting both CD8+ andCD4+ T cells. C. The addition 
of anti-CTLA-4 mAb could further support these TIL’s life and prevent de novo generation 
of Treg cells D. Following a resting period to limit the chances of autoimmune reactions, 
concomitant challenge with a dendritic cell vaccine loaded processed tumor peptide and 
GM-CSF could then further expand the tumor specific immune response of the ACT. E. IL-
15a therapy could also be administered during vaccination protocol to stimulate and expand 
T cell responsive with significantly less toxicity than through IL-2 addition. 
immunomodulatory mechanism employed by tumors to evade the immune system. Much 
work will be needed to bring these theoretical ideals into clinical reality, but through 
improved understanding of melanoma tumors and their ability to modulate the immune 
environment, substantial gains can be made in both therapeutic design and patient care.  
7. Conclusions 
The future looks promising for melanoma immunotherapy, even with the multiple 
disadvantages that research scientists and clinicians face from the disease. This chapter 
attempted to summarize the multiple steps of immunomodulation that melanoma tumors 
employ to thwart even the most well thought out therapy strategies. By understanding both 
the mechanisms tumors employ to suppress and abuse the immune system and the ways 
that previous immunotherapy strategies have failed to meet our expectation, we can move 
forward in devising new strategies in improved immunotherapeutics and disease 
management. These improved concepts include combining chemotherapy and 
immunotherapy strategies in new ways to more effectively shift the balance of the tumor 
microenvironment from immunosuppressive to immunostimulatory prior to immunological 
intervention, and the targeting of protumorigenic pathways like the BRAF/MAPK and 
STAT3 pathways to aid in tumor destruction and promote immune responses. Improved 
understanding of the defective Ag processing and presentation pathways in melanoma 
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presents novel targeting strategies through genetic manipulation of tumors by induction of 
GILT capable of generating novel immunogenic Ags/peptides. The importance of 
incorporating strategies to expand and activate both CD8+ and CD4+ T cells will also help 
in the design and efficacy of ACT, whole-cell, and protein/peptide based vaccine therapy 
with improved durable immune responses and the development of immunological memory. 
New cytokine adjuvants like IL-15 and IL-7 may also expand the efficacy of these techniques 
and aid in the reduction of toxicity seen in IL-2 or IFNǂ strategies. Monoclonal antibodies 
like ipilimumab also represent the very near future in melanoma therapy following its 
recent FDA approval. More strategies combining these molecules with ACT and vaccine 
strategies should be explored as a means of enhancing the expansion and activation of 
immune cells and in avoiding immunosuppression induced by melanoma cells. More 
collaborative efforts need to be made between basic scientists, clinical investigators, and 
physicians to devise the best way to take discoveries made on the bench into the clinic, 
particularly in the immunomodulation of melanoma tumors. It appears that for every step 
we take forward in targeting melanoma, the tumors develop a new suppressive mechanism 
to avoid our efforts. These deficits must be understood and overcome for immunotherapy to 
become a true therapeutic option for late stage melanoma patients. As always our best 
weapon in the fight against melanoma is knowledge, and the collective knowledge gained 
from understanding melanoma immunomodulation will lead to the next generation of 
techniques capable of alleviating this deadly disease.  
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